masoprocol and Disease Exacerbation

masoprocol has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guo, L; Jia, Z; Li, B; Li, L; Li, ZF; Quan, MY; Tan, GJ; Wang, D; Wang, L	1
Desideri, S; Grossman, SA; Mikkelsen, T; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X	1
Ashfaq, R; Bernstein, HS; Brock, M; Deasel, M; Dhara, S; Forastiere, A; Hansel, DE; Harmon, J; Huang, RC; Maitra, A; Montgomery, E; Shimada, Y; Washington, MK	1

Trials

1 trial(s) available for masoprocol and Disease Exacerbation

Article	Year
Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro-oncology, 2012, Volume: 14, Issue:4 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Masoprocol; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome	2012

Other Studies

2 other study(ies) available for masoprocol and Disease Exacerbation

Article	Year
Nordihydroguaiaretic acid can suppress progression of experimental autoimmune encephalomyelitis. IUBMB life, 2018, Volume: 70, Issue:5 Topics: Animals; Demyelinating Diseases; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation; Heme Oxygenase-1; Immediate-Early Proteins; Immunologic Factors; Injections, Intraperitoneal; Masoprocol; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Protein Serine-Threonine Kinases	2018
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. The American journal of surgical pathology, 2005, Volume: 29, Issue:3 Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis	2005

Article

Year

Nordihydroguaiaretic acid can suppress progression of experimental autoimmune encephalomyelitis.

IUBMB life, 2018, Volume: 70, Issue:5

Topics: Animals; Demyelinating Diseases; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation; Heme Oxygenase-1; Immediate-Early Proteins; Immunologic Factors; Injections, Intraperitoneal; Masoprocol; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Protein Serine-Threonine Kinases

2018

CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

The American journal of surgical pathology, 2005, Volume: 29, Issue:3

Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis

2005